Case Study

A Successful Approach For Managing Unexpected Increases In Potency For HPAPIs

Source: FAREVA

By Daniela Kovats, Fareva

Fareva1

Abstract: Contract development and manufacturing organizations (CDMOs) face the challenge of managing new active pharmaceutical ingredients (APIs) in development projects with less toxicity and pharmacology data than is sufficient to calculate an occupational exposure limit (OEL). That can be a risk when the drug substance is a potent compound. When Fareva Excella realized that a development project initially classified as an occupational exposure band (OEB)-4 highly potent API (HPAPI) had been later reclassified as an OEB-6 compound, the company upgraded a state-of-the-art containment production line to ensure operator safety and keep the project on track in less than one year.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: